Athanor Capital’s Fate Therapeutics FATE Stock Holding History

Athanor Capital’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,348	Closed	-$276K	–	544
2021 Q1	$276K	Buy	+3,348	New	+$321K	0.01%	610

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Athanor Capital's FATE Position: Q2 2021 in Review

Athanor Capital sold out of Fate Therapeutics (FATE) in Q2 2021, closing a stake of 3,348 shares — an estimated $276K sold.

Athanor Capital first reported a position in FATE in Q1 2021 and held it in 1 quarter. The position peaked at $276K in Q1 2021. 272 funds tracked by Wall St. Rank hold FATE as of Q2 2021.

Athanor Capital reported no remaining Fate Therapeutics position as of Q2 2021 after selling out during the quarter.
Athanor Capital sold 3,348 Fate Therapeutics shares in Q2 2021, an estimated $276K.
Athanor Capital first reported a position in Fate Therapeutics in Q1 2021 and held it in 1 quarter.
Athanor Capital's Fate Therapeutics position peaked at $276K in Q1 2021.
272 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.